Ralph A. DeFronzo, MD, discusses the utilization of glucagon-like peptide-1 agonists and incorporating evidence-based guidelines into practice when considering the use of incretin-based therapies for type 2...
In this video, Million Hearts® Executive Director Laurence Sperling, MD, overviews the 3 pillars of cardiovascular event prevention and how you can implement them into your practice.
In this video, Lindsay T. Fourman, MD, talks about how non-alcoholic fatty liver disease affects patients with HIV differently than it effects the general public.
According to William Boden, MD, the COURAGE Risk Prediction Tool is one of the most important developments to come from the COURAGE Trial. In this video, Dr Boden explains how the the tool works and what...
